




Attorney Docket No.: 6161.200-US
USSN: 09/867,277
Express Mail Label No.: EV 409530593 US

Remarks

Claims 1-38 have been cancelled. New claims 39-44 have been presented. The new claims are not believed to be objectionable and should overcome the Examiner's previous objections. Additionally, the new wording of these claims should moot the Examiner's 112 rejections.

New claims 39-44 are not anticipated by Castellano et al. as they require two separate modules, each for performing a separate task where each module is controlled by the same processor and wherein the replaceable module is not functional unless and until it is interfaced with the processor of the basis module. Castellano, on the other hand contemplates two separate, yet fully function devices, that may communicate with each other. In contrast, applicants are claiming at least two apparatuses, one of which is inoperable until combined with the other. In particular, the present claims require that the replaceable module be controlled by the processor of the basis module. Without that control, the replaceable module is inoperable.

New claims 39-44 are also not obvious in view of Castellano and Brown, Castellano and Cooper, or Castellano and Kovelman, as none of these documents disclose a multi module device wherein one module is inoperable until and unless coupled with the other module and wherein the processor of one module is needed to control the other module in order to make it function.



Attorney Docket No.: 6161.200-US
USSN: 09/867,277
Express Mail Label No.: EV 409530593 US

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: April 13, 2004



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE